Zobrazeno 1 - 10
of 204
pro vyhledávání: '"Danoprevir"'
Autor:
Yunjing Zhou, Minfeng Liang, Yiting Li, Xing Chen, Jie Yang, Honglian Bai, Yingzi Long, Xiaohong Zhang, Chaoshuang Lin
Publikováno v:
BMC Gastroenterology, Vol 24, Iss 1, Pp 1-6 (2024)
Abstract Background Sofosbuvir/Velpatasvir (Epclusa, ECS) is the first pan-genotype direct-acting antiviral agent (DAA) for hepatitis C virus (HCV) infection, and Danoprevir (DNV) is the first DAA developed by a Chinese local enterprise, which is sui
Externí odkaz:
https://doaj.org/article/dd38705deae74d5c9785e10b82c07fd7
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Drug Design, Development and Therapy, Vol Volume 14, Pp 2759-2774 (2020)
Miao Miao,1 Xixi Jing,1 Erik De Clercq,2 Guangdi Li1 1Hunan Provincial Key Laboratory of Clinical Epidemiology, Xiangya School of Public Health, Central South University, Changsha 410078, People’s Republic of China; 2Department of Microbiology, Imm
Externí odkaz:
https://doaj.org/article/26cd420240b144fd820aab9e64c6c8b1
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
BioImpacts. 12:315-324
Introduction: COVID-19 has spread out all around the world and seriously interrupted human activities. Being a newfound disease, not only many aspects of the disease are unknown, but also there is not an effective medication to cure the disease. Besi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c837e49d8359698debb5bf739d574c67
https://doi.org/10.34172/bi.2021.40
https://doi.org/10.34172/bi.2021.40
Autor:
Pleško, Ema
Celična terapija s celicami CAR-T je povzročila izredno učinkovite ter v nekaterih primerih trajne klinične rezultate pri zdravljenju raka. Vseeno pa pri terapiji s celicami CAR-T obstajajo omejitve, vključno s smrtno nevarnim sindromom sprošč
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______3505::04a7734c0c88f1c020f9642364f9c5cf
https://repozitorij.uni-lj.si/IzpisGradiva.php?id=138993
https://repozitorij.uni-lj.si/IzpisGradiva.php?id=138993
Autor:
Sekhar Talluri
Publikováno v:
Combinatorial Chemistry & High Throughput Screening. 24:716-728
Aims: To predict potential drugs for COVID-19 by using molecular docking for virtual screening of drugs approved for other clinical applications. Background: SARS-CoV-2 is the betacoronavirus responsible for the COVID-19 pandemic. It was listed as a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9c38e4b2f0936e82ac2618823319e477
https://doi.org/10.2174/13862073mta5smtezz
https://doi.org/10.2174/13862073mta5smtezz
Publikováno v:
Fungal Biology. 125:378-388
Candida haemulonii species complex (C. haemulonii, C. haemulonii var. vulnera and Candida duobushaemulonii) is composed by emerging and multidrug-resistant (MDR) yeasts. Candidiasis, the disease caused by these species, is difficult to treat and culm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aa866627e5d905100d42c03b67175d88
https://doi.org/10.1016/j.funbio.2020.12.004
https://doi.org/10.1016/j.funbio.2020.12.004
Publikováno v:
Drug Design, Development and Therapy. 14:2759-2774
On June 8, 2018, an NS3/4A protease inhibitor called danoprevir was approved in China to treat the infections of HCV genotype (GT) 1b - the most common HCV genotype worldwide. Based on phase 2 and 3 clinical trials, the 12-week regimen of ritonavir-b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fb817a9ef6951db8e96d3e2fb73c55d7
https://doi.org/10.2147/dddt.s254754
https://doi.org/10.2147/dddt.s254754
Autor:
Li Wang, Xuping Peng, Xianglin Tu, Shumei Wang, Donghong Zhu, Weihua Ju, Yanxia Huang, Hongyi Chen, Huabao Sun, Zhicheng Zhang, Jianfeng Rao, Xue Li
Publikováno v:
Journal of Medical Virology
BackgroundIn late December 2019, the coronavirus disease 2019 (COVID-19) first outbroke in Wuhan city, China, and has now become a global pandemic. However, there is no specific antiviral treatment for COVID-19.MethodsThis study was approved by the E
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::42eec961bb2fe5b40feb0d78e77682cf
https://doi.org/10.1002/jmv.26141
https://doi.org/10.1002/jmv.26141